Swixx BioPharma

✨ Celebrating a Remarkable Year at Swixx Biopharma ✨ 2024 marks 10 years since the start of our operations, and we reflect with pride on a year of growth, achievement, and impact: 🌍 Expanded our global reach into LATAM through a strategic combination with Biopas. 🤝 Continued to unlock access to life-saving medicines for patients in need across all countries and regions where we operate. 📈 Strengthened our presence in MENA, preparing to bring vital therapies closer to those who need them. 🌿 Published our ESG Strategy Framework, reinforcing our commitment to sustainability and responsibility. 🏆 Honored with prestigious awards and recognitions, including: - Inclusion in the FT1000 list of Europe’s fastest-growing companies by the Financial Times. - PMEA Awards: Winner in Excellence in Engagement through Digital Channels and New Technology for our Swixx Rare Disease Academy platform, and Highly Commended in Excellence in Rare Diseases. A heartfelt thank you to our dedicated employees for their passion, commitment, and hard work—your efforts are the foundation of our success! As we look ahead, we remain steadfast in our mission to serve our patients and partners. Thank you for your continued trust and collaboration! 🎄Wishing everyone a joyful holiday season and a successful New Year 2025! #SwixxBiopharma #PartnerforPharma #10Anniversary #ESGLeadership

🌟 Exciting News from Swixx BioPharma Rare Disease Business Unit! 🌟 We are incredibly proud to announce that the Swixx BioPharma Rare Disease Academy platform has achieved impressive results at the 2024 PMEA Awards! 🏆 Winner: Excellence in Engagement through Digital Channels and New Technology 🌟 Highly Commended: Excellence in Rare Diseases or Orphan Drugs The PMEA judges praised the platform for its innovative use of digital tools and its tailored approach to the needs of healthcare professionals involved in rare disease management. By centralizing high-quality educational content across 20 CEE countries, the Academy empowers HCPs with continuous learning opportunities on 15 rare diseases, supporting better patient outcomes. This achievement reflects the dedication and collaboration of our entire team and partners, especially our country teams, whose efforts have been instrumental in making the Academy a trusted resource for rare disease education. We remain committed to advancing digital education and supporting the HCP community with impactful solutions. Thank you to everyone who contributed to this milestone! 🙌 Irena Hampel Hrsak Vukasin Andric Renata Hrupelj Vedrana Sokac Brataljenovic #Swixx #PMEA2024 #RareDiseases #Teamwork #PartnerforPharma

🚀 We are thrilled to announce that Swixx BioPharma has been selected as a finalist in two categories at the prestigious PMEA Awards 2024 for our Swixx Rare Disease Academy project! 🎉 🧬 Excellence in Rare Diseases or Orphan Drugs 🖥️ Excellence in Engagement through Digital Channels and New Technology   The Swixx Rare Disease Academy is a cutting-edge digital platform designed to support healthcare professionals across Central and Eastern Europe, providing access to educational resources, webinars, and tools for 15 rare diseases. Through this platform, we aim to enhance collaboration, foster continuous learning, and ultimately improve patient outcomes in the region. This recognition is a testament to our team's dedication and passion for making a difference in the rare disease community. Thank you to all physicians, Patient Groups, Swixx country and HQ teams and everyone involved in this journey! 💡   #SwixxBioPharma #RareDiseases #PartnerforPharma #ExcellenceAwards #PMEA2024

🌍 Swixx Hematology Summit Brings Together CEE Experts and World-Class International Faculty We're excited to share that Swixx BioPharma, a partner of BeiGene in 13 Central and Eastern European (CEE) countries and Greece, organized a highly successful Hematology Summit in Ljubljana, Slovenia. This dynamic event brought together around 50 hematologists from CEE countries, focusing on cutting-edge advancements in the treatment of Chronic lymphocytic leukemia (CLL) and indolent lymphomas. With the participation of an esteemed international faculty, the summit provided an invaluable platform for exchanging knowledge and fostering collaboration among hematology experts. Together, we are paving the way toward improved patient outcomes in CLL, Waldenström's Macroglobulinemia, and Marginal Zone Lymphoma. A big thank you to everyone who contributed to making this summit such a memorable and impactful event, our esteemed Speaker faculty, and all participants on their continuous engagement during the meeting 👏   #HematologySummit #CLL #Hematology #SwixxBioPharma #PartnerforPharma #BeiGene 

🚀 We’re excited to share that Swixx BioPharma has been featured in The Financial Times as part of the "Breaking Borders in Business" series, in collaboration with Citi. The article highlights our strategic expansion into Latin America and beyond, showcasing our innovative approach to partnering with large and mid-sized biopharma companies. 🌍 It explores how our professional services and strategic acquisitions have strengthened our position as a preferred partner for multinationals, driving our growth and setting the stage for further expansion. 📈 Read more about our 10-year journey and future plans here: https://lnkd.in/d_KgkuZu. To find out more about Swixx BioPharma, visit our website https://lnkd.in/df9rHayV. #Swixx #PartnerforPharma #10Years #CelebratingaDecadeofImprovingLives

🌍 Swixx BioPharma is proud to announce the launch of our Environmental, Social, and Governance (ESG) Strategy Framework! Leveraging our decade of growth across CEE, Eurasia, MENA, and LATAM, our new ESG strategy focuses on 5 key pillars: 1️ Put People First 2️ Ensure Access to Medicines 3️ Strengthen Community Partnerships 4️ Preserve the Environment 5️ Foster Sustainable Corporate Governance At Swixx BioPharma, we see ESG not just as a regulatory requirement, but as an opportunity to drive transparency, accountability, and meaningful impact for our stakeholders and communities. 🌱🤝 Read the full announcement on our website: https://lnkd.in/drqAUYz5 Access our ESG page to learn more about our journey toward a sustainable future! https://lnkd.in/dGBVrZGz #ESG #Sustainability #CorporateResponsibility #Swixx #PartnerforPharma  

🎉 We are thrilled to kick off the celebration of our 10-year anniversary! Ten years ago, we started our journey in Serbia with a small team of enthusiasts determined to make a difference. Since then, we've grown to a company with presence in CEE, Eurasia/CIS, MENA and LATAM, becoming a reliable partner in our communities, a trusted ally to healthcare providers, and a professional service provider to multinational companies. To mark a first decade of hard work, dedication, and success, we are excited to unveil our updated logo featuring a special 10-year mark and the tagline: "Celebrating a First Decade of Improving Lives". Check out our new logo on our website and social media starting today and join us in celebrating this milestone of our tremendous journey! #10Years #Anniversary #Swixx #PartnerforPharma

We are delighted to announce the appointment of Piret Tuul as our new Regional Baltic General Manager for Lithuania, Latvia, and Estonia. Piret brings over 28 years of experience in the pharmaceutical industry, including roles at Schering-Plough, Roche, Novartis, and Takeda. Her impressive career includes various positions in sales, marketing, regulatory, and business management, with increasing responsibilities and covered geographies and significant achievements in oncology, rare diseases, and other specialized therapies. Piret Tuul's academic background includes a B.Sc. in Biology, an M.Sc. in Biochemistry, and an MBA in Marketing and Health Economy from Tartu University, Estonia. Her leadership and strategic skills have driven business growth, product launches, and successful integrations. We are convinced that her proven people management skills and industry and therapeutic area knowledge will reinforce the growth of our local organization. Welcome to Swixx, Piret! #Swixx #PartnerforPharma #newemployee #welcometotheteam

🌎 Important news from Swixx BioPharma We are delighted to announce the closing of the acquisition of Laboratorios Biopas, a leading marketing and distribution company for international biopharmaceutical firms in the Latin America. The combination with Laboratorios Biopas extends & transforms Swixx BioPharma's geographical footprint creating a compelling, single-stop, multi-continent partner for biopharma companies in Central and Eastern Europe, CIS/Eurasia, MENA and now Latin America. Jean-Michel Lespinasse, CEO of Swixx BioPharma, commented: “We are thrilled to welcome Biopas into the Swixx BioPharma family. Building on our matching cultures and vision, the combined entity firmly moves forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals.” You can access the full Press release on our website here: https://lnkd.in/d6szV3Hv #Swixx #PartnerforPharma #BusinessExpansion #Biopas

🚀 Exciting News from Swixx BioPharma 🌎 We are thrilled to announce our strategic expansion into Latin America with the signature of an agreement to acquire the equity of Pharma Consulting Group S.A., the holding company of Laboratorios Biopas, a leading marketing and distribution company for international biopharmaceutical firms in the region. Through Laboratorios Biopas’ comprehensive Latam continental coverage, Swixx BioPharma will now be able to provide a compelling, single-stop, multi-continent solution for biopharma companies with the coverage of Central and Eastern Europe, CIS/Eurasia, MENA and now Latin America. 🌍💊 The transaction is set to close between June and July 2024. With over 1,300 employees and being recognized by the Financial Times as one of Europe’s fastest growing companies in 2024, the expansion marks another important step towards fulfilling Swixx BioPharma’s mission to become the preferred partner for biopharma companies seeking indirect routes to launch and commercialize their medicines. 🤝 We are committed to seamless business continuity, therefore the Biopas leadership team remains at the helm of the combined company in Latam and Biopas name is retained for Latam operations. You can access the full Press release on our website here: https://lnkd.in/dRan-qPC #Swixx #PartnerforPharma #BusinessExpansion